FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1567165257> ?p ?o ?g. }

• W1567165257 endingPage "2018" @default.
• W1567165257 startingPage "2012" @default.
• W1567165257 abstract "Interferon-alpha (IFN-alpha) has shown significant activity in the treatment of BCR-ABL-negative myeloproliferative disorders (MPDs), particularly essential thrombocythemia (ET) and polycythemia vera (PV). PEG-IFN-alpha-2b is a pegylated IFN-alpha-2b with a significant advantage over nonpegylated form in that it is administered once a week.Thirty-eight patients with BCR-ABL-negative MPDs were treated with PEG-IFN-alpha-2b, given subcutaneously weekly, at the starting dose of 3 microg/kg/wk for the first 14 patients and then 2 microg/kg/wk for the next 24 patients, with intent to treat patients as long as they benefited from the therapy.Median age was 54 years. Patient diagnoses were: 13 (34%) ET; 11 (29%) primary myelofibrosis (PMF); 5 (13%) BCR-ABL-negative chronic myeloid leukemia (CML); 4 (10.5%) hypereosinophilic syndrome (HES); 4 (10.5%) PV; and 1 (3%) unclassified myeloproliferative disease (uMPD). Recorded grade 3-4 toxicities were related to fatigue, myelosuppression, and musculoskeletal pain. Ten (26%) patients stopped treatment because of toxicity. Thirteen (34%) patients achieved a complete remission, and 4 (11%) achieved a partial response. Only 1 patient with PMF responded. Median time to response was 5 months. Median duration of response was 20 months. Three patients had a sustained response for >24 months.PEG-IFN-alpha-2b, with proper dose modifications, is effective in controlling disease in a significant proportion of BCR-ABL-negative MPD patients, particularly ET and PV. However, toxicities encountered with PEG-IFN-alpha-2b therapy are similar to those obtained with conventional IFN-alpha, thus limiting the duration of therapy." @default.
• W1567165257 created "2016-06-24" @default.
• W1567165257 creator A5014462961 @default.
• W1567165257 creator A5015140142 @default.
• W1567165257 creator A5026347795 @default.
• W1567165257 creator A5028845635 @default.
• W1567165257 creator A5038307470 @default.
• W1567165257 creator A5049385583 @default.
• W1567165257 creator A5061026876 @default.
• W1567165257 creator A5061285204 @default.
• W1567165257 creator A5085521139 @default.
• W1567165257 creator A5087340949 @default.
• W1567165257 creator A5090435894 @default.
• W1567165257 date "2007-01-01" @default.
• W1567165257 modified "2023-10-17" @default.
• W1567165257 title "PEG-IFN-α-2b therapy in BCR-ABL–negative myeloproliferative disorders" @default.
• W1567165257 cites W141079205 @default.
• W1567165257 cites W1517300131 @default.
• W1567165257 cites W1519361392 @default.
• W1567165257 cites W1523899401 @default.
• W1567165257 cites W1975477926 @default.
• W1567165257 cites W1982989509 @default.
• W1567165257 cites W1999025699 @default.
• W1567165257 cites W2014449381 @default.
• W1567165257 cites W2015080428 @default.
• W1567165257 cites W2020348444 @default.
• W1567165257 cites W2065225927 @default.
• W1567165257 cites W2078051582 @default.
• W1567165257 cites W2079634214 @default.
• W1567165257 cites W2099264304 @default.
• W1567165257 cites W2104278356 @default.
• W1567165257 cites W2147349522 @default.
• W1567165257 cites W2156574153 @default.
• W1567165257 doi "https://doi.org/10.1002/cncr.23018" @default.
• W1567165257 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17849460" @default.
• W1567165257 hasPublicationYear "2007" @default.
• W1567165257 type Work @default.
• W1567165257 sameAs 1567165257 @default.
• W1567165257 citedByCount "104" @default.
• W1567165257 countsByYear W15671652572012 @default.
• W1567165257 countsByYear W15671652572013 @default.
• W1567165257 countsByYear W15671652572014 @default.
• W1567165257 countsByYear W15671652572015 @default.
• W1567165257 countsByYear W15671652572016 @default.
• W1567165257 countsByYear W15671652572017 @default.
• W1567165257 countsByYear W15671652572018 @default.
• W1567165257 countsByYear W15671652572019 @default.
• W1567165257 countsByYear W15671652572020 @default.
• W1567165257 countsByYear W15671652572021 @default.
• W1567165257 countsByYear W15671652572022 @default.
• W1567165257 countsByYear W15671652572023 @default.
• W1567165257 crossrefType "journal-article" @default.
• W1567165257 hasAuthorship W1567165257A5014462961 @default.
• W1567165257 hasAuthorship W1567165257A5015140142 @default.
• W1567165257 hasAuthorship W1567165257A5026347795 @default.
• W1567165257 hasAuthorship W1567165257A5028845635 @default.
• W1567165257 hasAuthorship W1567165257A5038307470 @default.
• W1567165257 hasAuthorship W1567165257A5049385583 @default.
• W1567165257 hasAuthorship W1567165257A5061026876 @default.
• W1567165257 hasAuthorship W1567165257A5061285204 @default.
• W1567165257 hasAuthorship W1567165257A5085521139 @default.
• W1567165257 hasAuthorship W1567165257A5087340949 @default.
• W1567165257 hasAuthorship W1567165257A5090435894 @default.
• W1567165257 hasConcept C126322002 @default.
• W1567165257 hasConcept C203014093 @default.
• W1567165257 hasConcept C2776178377 @default.
• W1567165257 hasConcept C2778729363 @default.
• W1567165257 hasConcept C2778837598 @default.
• W1567165257 hasConcept C2779282312 @default.
• W1567165257 hasConcept C2780007613 @default.
• W1567165257 hasConcept C2780076729 @default.
• W1567165257 hasConcept C2781057849 @default.
• W1567165257 hasConcept C2781228144 @default.
• W1567165257 hasConcept C2909179924 @default.
• W1567165257 hasConcept C2910274570 @default.
• W1567165257 hasConcept C71924100 @default.
• W1567165257 hasConcept C90924648 @default.
• W1567165257 hasConceptScore W1567165257C126322002 @default.
• W1567165257 hasConceptScore W1567165257C203014093 @default.
• W1567165257 hasConceptScore W1567165257C2776178377 @default.
• W1567165257 hasConceptScore W1567165257C2778729363 @default.
• W1567165257 hasConceptScore W1567165257C2778837598 @default.
• W1567165257 hasConceptScore W1567165257C2779282312 @default.
• W1567165257 hasConceptScore W1567165257C2780007613 @default.
• W1567165257 hasConceptScore W1567165257C2780076729 @default.
• W1567165257 hasConceptScore W1567165257C2781057849 @default.
• W1567165257 hasConceptScore W1567165257C2781228144 @default.
• W1567165257 hasConceptScore W1567165257C2909179924 @default.
• W1567165257 hasConceptScore W1567165257C2910274570 @default.
• W1567165257 hasConceptScore W1567165257C71924100 @default.
• W1567165257 hasConceptScore W1567165257C90924648 @default.
• W1567165257 hasIssue "9" @default.
• W1567165257 hasLocation W15671652571 @default.
• W1567165257 hasLocation W15671652572 @default.
• W1567165257 hasOpenAccess W1567165257 @default.
• W1567165257 hasPrimaryLocation W15671652571 @default.
• W1567165257 hasRelatedWork W1523078789 @default.
• W1567165257 hasRelatedWork W2027789412 @default.

• next